4
Changes in Ownership
Taysha Gene Therapies, Inc. Filed Acc 0001665124-26-000002
President and Head of R&D sold 200,000 shares at $4.71 ($942,000)
- President and Head of R&D acquired 200,000 shares (option exercise)
- President and Head of R&D acquired 427,000 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar President and Head of R&D | 2026-01-12 | Option exercise 10b5-1 | +111,324 | $0.70 | $77,804 | 1,117,763 | D |
| Nagendran Sukumar President and Head of R&D | 2026-01-12 | Option exercise 10b5-1 | +88,676 | $1.71 | $151,636 | 1,206,439 | D |
| Nagendran Sukumar President and Head of R&D | 2026-01-12 | Sale 10b5-1 | −200,000 | $4.71 | $942,000 | 1,006,439 | D |
| Nagendran Sukumar President and Head of R&D | 2026-01-12 | Grant or award 10b5-1 | +427,000 | 1,433,439 | D | ||
| Derivatives | |||||||
| Nagendran Sukumar President and Head of R&D | 2026-01-12 | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −111,324 | 111,359 | D | ||
| Nagendran Sukumar President and Head of R&D | 2026-01-12 | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −88,676 | 474,941 | D | ||
| Nagendran Sukumar President and Head of R&D | 2026-01-12 | Grant or award · Employee Stock Option (right to buy) 10b5-1 | +274,000 | 274,000 | D | ||
| Open-market sales · 200,000 sh · avg $4.71 · $942,000 | |||||||
Loading xslF345X05/form4-01142026_040101.xml…